SML0178
ARL-17477 dihydrochloride hydrate
≥98% (HPLC)
别名:
N-[4-[2-[[(3-chlorophenyl)methyl]amino]ethyl]phenyl]-2-thiophenecarboximidamide dihydrochloride hydrate
登录并加购，请在购物车里查看协议价、货期和发货地。
选择规格
变更视图
关于此项目
经验公式（希尔记法）:
C20H20ClN3S·2HCl · xH2O
化学文摘社编号:
分子量:
442.83 (anhydrous basis)
NACRES:
NA.77
PubChem Substance ID:
UNSPSC Code:
12352202
MDL number:
Assay:
≥98% (HPLC)
Form:
powder
Storage condition:
desiccated
Quality Segment
assay
≥98% (HPLC)
form
powder
storage condition
desiccated
color
white to beige
solubility
H2O: ≥5 mg/mL
originator
AstraZeneca
storage temp.
2-8°C
SMILES string
O.Cl.Cl.Clc1cccc(CNCCc2ccc(NC(=N)c3cccs3)cc2)c1
InChI
1S/C20H20ClN3S.2ClH.H2O/c21-17-4-1-3-16(13-17)14-23-11-10-15-6-8-18(9-7-15)24-20(22)19-5-2-12-25-19;;;/h1-9,12-13,23H,10-11,14H2,(H2,22,24);2*1H;1H2
InChI key
QOPATWWWZNTSQF-UHFFFAOYSA-N
Application
ARL-17477 dihydrochloride hydrate may be used in cell signaling studies.
Biochem/physiol Actions
ARL-17477 dihydrochloride hydrate is a selective nNOS inhibitor
ARL-17477 is an nNOS specific inhibitor. The IC50 against rat nNOS is 35 nM and it has 100-fold selectivity over endothelial and inducible isoforms. ARL-17477 penetrates the brain, and reduces infarct size and reduces cerebral blood flow in several different rodent models of ischemic brain injury.
Features and Benefits
This compound was developed by AstraZeneca. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
signalword
Warning
hcodes
Hazard Classifications
Acute Tox. 4 Oral - Eye Irrit. 2
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable